Form 4: BioRestorative Therapies CFO Acquires Stock Options
SEC Form 4 Filing
Robert Eugene Kristal, CFO of BioRestorative Therapies, Inc., reports acquisition of stock options.
Summary
- Robert Eugene Kristal, the Chief Financial Officer of BioRestorative Therapies, Inc., filed a Form 4.
- The report details changes in his beneficial ownership of company securities.
- Kristal acquired stock options for 166,492 shares of common stock at an exercise price of $2.46 on February 14, 2025.
- These options vest in installments, starting with 83,246 shares on February 14, 2025, and the remainder vesting quarterly thereafter until fully vested.
- Kristal directly owns 7,994 shares of common stock.
- He also holds options for 10,490 shares (exercisable at $5.08, expiring 11/04/2031), 88,968 shares (exercisable at $2.91, expiring 02/17/2033), and 263,158 shares (exercisable at $1.45, expiring 02/13/2034).
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports the acquisition of stock options by the CFO, which could be interpreted as a positive sign but doesn't provide enough information to warrant a strong positive sentiment.
Positives
- The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. They are closely watched by investors for signals about management's confidence in the company's prospects.
Stakeholder Impact
- The acquisition of stock options by the CFO could potentially boost investor confidence.
Key Dates
| Date | Description |
|---|---|
| 02/17/2023 | 44,484 shares of stock options exercisable at $2.91 vest. |
| 02/13/2024 | 131,579 shares of stock options exercisable at $1.45 vest. |
| 02/17/2024 | Quarterly vesting of 44,484 shares of stock options exercisable at $2.91 begins. |
| 02/14/2025 | Acquisition date of 166,492 stock options exercisable at $2.46; 83,246 shares vest. |
| 02/13/2025 | Quarterly vesting of 131,579 shares of stock options exercisable at $1.45 begins. |
| 02/14/2026 | Quarterly vesting of 83,246 shares of stock options exercisable at $2.46 begins. |
| 11/04/2031 | Expiration date of stock options exercisable at $5.08. |
| 02/17/2033 | Expiration date of stock options exercisable at $2.91. |
| 02/13/2034 | Expiration date of stock options exercisable at $1.45. |
| 02/14/2035 | Expiration date of stock options exercisable at $2.46. |
Keywords
Form 4, BioRestorative Therapies, BRTX, Robert Kristal, CFO, stock options, beneficial ownership, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.